FR2903984B1 - Derives d'imidazolones substitues, preparation et utilisations - Google Patents

Derives d'imidazolones substitues, preparation et utilisations

Info

Publication number
FR2903984B1
FR2903984B1 FR0606752A FR0606752A FR2903984B1 FR 2903984 B1 FR2903984 B1 FR 2903984B1 FR 0606752 A FR0606752 A FR 0606752A FR 0606752 A FR0606752 A FR 0606752A FR 2903984 B1 FR2903984 B1 FR 2903984B1
Authority
FR
France
Prior art keywords
preparation
imidazolone derivatives
substituted
substituted imidazolone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0606752A
Other languages
English (en)
French (fr)
Other versions
FR2903984A1 (fr
Inventor
Edith Bouey
Christophe Masson
Karine Bertrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0606752A priority Critical patent/FR2903984B1/fr
Application filed by Genfit SA filed Critical Genfit SA
Priority to JP2009521318A priority patent/JP2009544675A/ja
Priority to MX2009000900A priority patent/MX2009000900A/es
Priority to EA200900211A priority patent/EA200900211A1/ru
Priority to EP07823633A priority patent/EP2049107A2/fr
Priority to NZ575011A priority patent/NZ575011A/en
Priority to US12/309,642 priority patent/US20100004159A1/en
Priority to KR1020097003832A priority patent/KR20090038469A/ko
Priority to BRPI0715326-0A priority patent/BRPI0715326A2/pt
Priority to CA002658625A priority patent/CA2658625A1/fr
Priority to AU2007279135A priority patent/AU2007279135A1/en
Priority to PCT/FR2007/051716 priority patent/WO2008012470A2/fr
Priority to CNA2007800352070A priority patent/CN101522192A/zh
Publication of FR2903984A1 publication Critical patent/FR2903984A1/fr
Application granted granted Critical
Publication of FR2903984B1 publication Critical patent/FR2903984B1/fr
Priority to IL196671A priority patent/IL196671A0/en
Priority to NO20090348A priority patent/NO20090348L/no
Priority to ZA200901268A priority patent/ZA200901268B/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0606752A 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations Expired - Fee Related FR2903984B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR0606752A FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations
AU2007279135A AU2007279135A1 (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparation and uses
EA200900211A EA200900211A1 (ru) 2006-07-24 2007-07-24 Замещенные производные имидазолона, их получение и применение
EP07823633A EP2049107A2 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
NZ575011A NZ575011A (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparation and uses
US12/309,642 US20100004159A1 (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparations and uses
KR1020097003832A KR20090038469A (ko) 2006-07-24 2007-07-24 치환된 이미다졸론 유도체, 그 제조 및 용도
BRPI0715326-0A BRPI0715326A2 (pt) 2006-07-24 2007-07-24 compostos derivados de imidazolonas polissubstituÍdas, composiÇço farmacÊutica e, uso de pelo menos um composto
JP2009521318A JP2009544675A (ja) 2006-07-24 2007-07-24 置換されたイミダゾロン誘導体、製造方法及び使用
MX2009000900A MX2009000900A (es) 2006-07-24 2007-07-24 Derivados de imidazolonas sustituidas, preparacion y usos.
PCT/FR2007/051716 WO2008012470A2 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
CNA2007800352070A CN101522192A (zh) 2006-07-24 2007-07-24 取代的咪唑啉酮衍生物、制备和用途
CA002658625A CA2658625A1 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
IL196671A IL196671A0 (en) 2006-07-24 2009-01-22 Substituted imidazolone derivatives, preparation and uses
NO20090348A NO20090348L (no) 2006-07-24 2009-01-22 Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
ZA200901268A ZA200901268B (en) 2006-07-24 2009-02-23 Substituted imidazolone derivatives, preparation and uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0606752A FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations

Publications (2)

Publication Number Publication Date
FR2903984A1 FR2903984A1 (fr) 2008-01-25
FR2903984B1 true FR2903984B1 (fr) 2008-10-03

Family

ID=37843186

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0606752A Expired - Fee Related FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations

Country Status (16)

Country Link
US (1) US20100004159A1 (https=)
EP (1) EP2049107A2 (https=)
JP (1) JP2009544675A (https=)
KR (1) KR20090038469A (https=)
CN (1) CN101522192A (https=)
AU (1) AU2007279135A1 (https=)
BR (1) BRPI0715326A2 (https=)
CA (1) CA2658625A1 (https=)
EA (1) EA200900211A1 (https=)
FR (1) FR2903984B1 (https=)
IL (1) IL196671A0 (https=)
MX (1) MX2009000900A (https=)
NO (1) NO20090348L (https=)
NZ (1) NZ575011A (https=)
WO (1) WO2008012470A2 (https=)
ZA (1) ZA200901268B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552209A4 (en) * 2010-03-26 2014-01-22 Merck Sharp & Dohme NEW SPIROIMIDAZOLON DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHOD FOR THEIR USE
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8633231B2 (en) 2010-07-13 2014-01-21 Merck Sharp & Dohme Corp. Substituted imidazolones, compositions containing such compounds and methods of use
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014209034A1 (en) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
WO2015095011A1 (en) 2013-12-17 2015-06-25 Janssen Pharmaceutica Nv Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104177298B (zh) * 2014-09-18 2018-10-02 湘潭大学 4,4-二取代-4,5-二氢-1h–咪唑-5-酮、衍生物及其合成方法
MX386470B (es) 2015-07-17 2025-03-18 Pasteur Institut Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
JP2018526411A (ja) * 2015-09-11 2018-09-13 ラクオリア創薬株式会社 Ｔｒｐｍ８拮抗剤としてのイミダゾリノン誘導体
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
BR112019000706A8 (pt) 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544812B2 (en) * 2001-11-30 2009-06-09 Eli Lilly And Company Peroxisome proliferator activated receptor agonists
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
FR2903984A1 (fr) 2008-01-25
MX2009000900A (es) 2009-06-18
AU2007279135A1 (en) 2008-01-31
JP2009544675A (ja) 2009-12-17
NZ575011A (en) 2011-12-22
WO2008012470A3 (fr) 2008-03-20
CN101522192A (zh) 2009-09-02
NO20090348L (no) 2009-04-24
WO2008012470A2 (fr) 2008-01-31
CA2658625A1 (fr) 2008-01-31
IL196671A0 (en) 2009-11-18
ZA200901268B (en) 2010-04-28
BRPI0715326A2 (pt) 2013-08-13
EA200900211A1 (ru) 2009-06-30
KR20090038469A (ko) 2009-04-20
US20100004159A1 (en) 2010-01-07
EP2049107A2 (fr) 2009-04-22

Similar Documents

Publication Publication Date Title
FR2903984B1 (fr) Derives d'imidazolones substitues, preparation et utilisations
FR20C1019I2 (fr) Promedicaments de composes de 2,4-pyrimidinediamine et leurs utilisations
HUS1900034I1 (hu) 6,7-telítetlen-7-karbamoil-szubsztituált morfinán-származékok
EP2124551A4 (en) SUBSTITUTED 1, 3-DIOXANES AND THEIR USE
EP1973405A4 (en) HYDROXYALKYLARYLAMID DERIVATIVES
NL2000371A1 (nl) Chromaan gesubstitueerde benzimidazoolderivaten.
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
EP2135188A4 (en) COMMON USE OF CORPORATE SAFETY ASSESSMENT
EP2366785A4 (en) OLIGONUCLEOTIDE DERIVATIVES, MARKING AGENTS AND THE MARKETING AGENT
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
EP2118093A4 (en) [1,2,3] -TRIAZOLYL-SUBSTITUTED CHINOLINE AND COUMARINE AS LEUKOTRIEN BIOSYNTHESIS INHIBITORS
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
ATE494290T1 (de) Substituierte 2,5-dihydro-3h-pyrazol-ä4,3-cü- pyridazin-3-on-derivate, ihre herstellung und ihre verwendung als cannibinoid-cb1- rezeptorliganden
EP1976511A4 (en) FLUORATED ARYLAMIDE DERIVATIVES
ATE507223T1 (de) N-cycloalkyl-carboxamid-, thiocarboxamid- und n- substitutierte carboximidamid-derivate als fungizide
FR2884516B1 (fr) Antagonistes npy, preparation et utilisations
IL187426A0 (en) Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
EP2152080A4 (en) NEW SOLUBLE 1,4-BENZODIAZEPINE COMPOUNDS AND STABLE SALT THEREOF
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila
IL235943A0 (en) Genistein salts, crystalline forms of same, compositions comprising same and uses thereof
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
NL1031473A1 (nl) Cyclopentapyridine- en tetrahydrochinolinederivaten.
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100331